Search

Your search keyword '"Stagno, F."' showing total 518 results
Start Over Author "Stagno, F."
518 results on '"Stagno, F."'

101. Imatinib long-term effects study: global independent assessment of imatinib in chronic myeloid leukemia: results at 7 years

Author

Gambacorti Passerini, C, Antolini, L, Piazza, R, Mahon, Fx, Guilhot, F, Deininger, M, Fava, Carmen, Nagler, A, Della Casa CM, Morra, E, Abruzzese, E, D’Emilio, A, Stagno, F, le Coutre, P, Monroy, Fh, Santini, V, Martino, B, Pane, F, Piccin, A, Giraldo, P, Assouline, S, Durosinmi, Ma, Leeksma, O, Pogliani, Em, Pavesi, F, Cecchetti, C, Altieri, C, Rizzo, C, Dilda, I, Mori, S, Kim, Dw, and Valsecchi, M. G.

Published
2011

102. Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?

Author

Latagliata, R., Breccia, M., Ferrero, D., Cavazzini, Francesco, Trawinska, M. M., Castagnetti, F., Annunziata, M., Stagno, F., Tiribelli, M., Imbergamo, S., Fava, C., Crisà, E., Pietrantuono, G., Gozzini, A., Falzetti, F., Montefusco, E., Iurlo, A., Musolino, C., Cedrone, M., Russo Rossi, A., Pregno, P., Visani, G., Capodanno, I., Mauro, E., Spadea, A., Giglio, G., Celesti, F., Sica, S., Storti, S., D'Addosio, A. M., Rege Cambrin, G., Luciano, L., Abruzzese, E., Rosti, G., and Alimena, G.

Published
2011

104. The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia

Author

Efficace, F., primary, Rosti, G., additional, Breccia, M., additional, Cottone, F., additional, Giesinger, J. M., additional, Stagno, F., additional, Iurlo, A., additional, Russo Rossi, A., additional, Luciano, L., additional, Martino, B., additional, Galimberti, S., additional, Turri, D., additional, Bergamaschi, M., additional, Tiribelli, M., additional, Fava, C., additional, Angelucci, E., additional, Mandelli, F., additional, and Baccarani, M., additional

Published
2015
Full Text
View/download PDF

105. Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment

Author

Russo, D, primary, Malagola, M, additional, Skert, C, additional, Cancelli, V, additional, Turri, D, additional, Pregno, P, additional, Bergamaschi, M, additional, Fogli, M, additional, Testoni, N, additional, De Vivo, A, additional, Castagnetti, F, additional, Pungolino, E, additional, Stagno, F, additional, Breccia, M, additional, Martino, B, additional, Intermesoli, T, additional, Cambrin, G R, additional, Nicolini, G, additional, Abruzzese, E, additional, Tiribelli, M, additional, Bigazzi, C, additional, Usala, E, additional, Russo, S, additional, Russo-Rossi, A, additional, Lunghi, M, additional, Bocchia, M, additional, D'Emilio, A, additional, Santini, V, additional, Girasoli, M, additional, Lorenzo, R Di, additional, Bernardi, S, additional, Palma, A Di, additional, Cesana, B M, additional, Soverini, S, additional, Martinelli, G, additional, Rosti, G, additional, and Baccarani, M, additional

Published
2015
Full Text
View/download PDF

106. LOW DOSE CONTINUOUS THERAPY WITH DASATINIB SIGNIFICANTLY IMPACT ON SURVIVAL OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML) RESISTANT OR INTOLERANT TO IMATINIB. RESULTS FROM A REAL LIFE-BASED ITALIAN MULTICENTER RETROSPECTIVE STUDY ON 114 UNSELECTED PATIENTS

Author

Visani, G, Breccia, M, Gozzini, A, Specchia, G, Montefusco, E, Morra, E, Annunziata, M, Luciano, L, Camera, A, Cavazzini, F, Stagno, F, Di Raimondo, F, Pregno, P, Santini, V, Piccaluga, P, Pacilli, M, Pungolino, E, Usala, E, Angelucci, E, Cuneo, A, Ferrara, F, Crugnola, M, Binotto, G, Maino, E, Latagliata, R, Nicolini, R, Barulli, S, Loscocco, F, Alimena, G, and Isidori, A

Published
2010

107. LOW DOSE CONTINUOUS THERAPY WITH DASATINIB SIGNIFICANTLY IMPACT ON SURVIVAL OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML) RESISTANT OR INTOLERANT TO IMATINIB. RESULTS FROM A REAL LIFE-BASED ITALIAN MULTICENTER RETROSPECTIVE STUDY ON 114 UNSELECTED PATIENTS

Author

Visani, G., Breccia, M., Gozzini, A., Specchia, G., Montefusco, E., Morra, E., Annunziata, M., Luciano, L., Camera, A., Cavazzini, Francesco, Stagno, F., Di Raimondo, F., Pregno, P., Santini, V., Piccaluga, P., Pacilli, M., Pungolino, E., Angelucci, E. Usala E., Cuneo, Antonio, Ferrara, F., Crugnola, M., Binotto, G., Maino, E., Latagliata, R., Nicolini, G., Barulli, S., Loscocco, F., Alimena, G., and Isidori, A.

Published
2010

109. MONITORING OF COMPLETE CYTOGENETIC RESPONSE (CCGR) BY INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION (I-FISH) ON PERIPHERAL BLOOD IN ELDERLY PH+ CML PATIENTS WITH STABLE CCGR TREATED WITH INTERMITTENT IMATINIB (IM)EUDRACT NUMBER 2007-005102-42, CLINICALTRIALS.GOV NCT 00858806

Author

Russo, Domenico, Malagola, Michele, Testoni, N, Martinelli, G, Colombi, C, Skert, C, Rosti, G, Amabile, M, Fogli, M, Mirto, S, Turri, D, Gobbi, M, Pierri, I, Vitolo, U, Pregno, P, Morra, E, Pungolino, E, Di Raimondo, F, Stagno, F, Foà, R, Alimena, G, Breccia, M, Nobile, F, Martino, B, Rambaldi, R, Intermesoli, T, Saglio, G, Rege Cambrin, G, Visani, G, Nicolini, G, De Fabritiis, P, Abruzzese, E, Fanin, R, Tiribelli, M, Galieni, P, Bigazzi, C, Liso, V, Specchia, G, Angelucci, E, Usala, E, Musolino, C, Russo, S, Gaidano, G, Lunghi, M, Lauria, F, Bocchia, M, Rodeghiero, F, D’Emilio, A, Bosi, A, Santini, V, Quarta, G, Girasoli, M, Fioritoni, G, Di Lorenzo, R, De Vivo, A, Soverini, S, Iacobucci, I, and Baccarani, M.

Published
2010

110. PRE-FINAL ANALYSIS OF THE PHASE II EXPLORATIVE STUDY OF INTERMITTENT IMATINIB (IM) TREATMENT (INTERIM) IN ELDERLY PH+ CML PATIENTS WITH STABLE COMPLETE CYTOGENETIC RESPONSE (CCGR) – EUDRACT NUMBER 2007-005102-42, CLINICALTRIALS.GOV NCT 00858806

Author

Russo, Domenico, Martinelli, G, Malagola, Michele, Colombi, C, Rosti, G, Amabile, M, Fogli, M, Mirto, S, Turri, D, Gobbi, M, Pierri, I, Vitolo, U, Pregno, P, Morra, E, Pungolino, E, Di Raimondo, F, Stagno, F, Foà, R, Alimena, G, Breccia, M, Nobile, F, Martino, B, Rambaldi, R, Intermesoli, T, Saglio, G, Rege Cambrin, G, Visani, G, Nicolini, G, De Fabritiis, P, Abruzzese, E, Fanin, R, Tiribelli, M, Galieni, P, Bigazzi, C, Liso, V, Specchia, G, Angelucci, E, Usala, E, Musolino, C, Russo, S, Gaidano, G, Lunghi, M, Lauria, F, Bocchia, M, Rodeghiero, F, D’Emilio, A, Bosi, A, Santini, V, Quarta, G, Girasoli, M, Fioritoni, G, and Di Lorenzo, R.

Published
2010

113. IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY PATIENTS WITH IMATINIB-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA

Author

Tiribelli, M., Latagliata, R., Breccia, M., Luciano, L., Castagnetti, F., Gozzini, A., Rege Cambrin, G., Annunziata, M., Pregno, P., Albano, F., Abruzzese, E., Musto, P., Sorà, F., Ferrero, D., Montefusco, E., Cavazzini, F., Binotto, G., Fanin, R., Stagno, F., Pane, F., Rosti, G., Santini, V., Fava, C., Alimena, G., and Paolo VIGNERI

Published
2010

114. CHARLSON COMORBIDITIES INDEX (CCI) MAY PREDICT COMPLIANCE AND DEVELOPMENT OF PLEURAL EFFUSIONS IN ELDERLY CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT PATIENTS TREATED WITH DASATINIB

Author

Breccia, M, Latagliata, R, Stagno, F, Luciano, L, Gozzini, A, Castagnetti, F, Ulisciani, S, Cavazzini, F, Annunziata, M, Sorà, F, Russo Rossi, A, Pregno, P, Porrini, R, Abruzzese, E, Giai, V, Musto, P, Tiribelli, M, Binotto, G, Occhini, U, Vallone, R, Martino, B, Capodanno, I, Spina, F, Pane, F, Santini, V, Rosti, G, Fava, C, and Alimena, G

Published
2010

118. IMATINIB 400 MG VS 800 MG DAILY AS A FRONT-LINE TREATMENT OF SOKAL HIGH-RISK PH+ CHRONIC MYELOID LEUKEMIA: 4-YEAR RESULTS OF A PROSPECTIVE RANDOMIZED STUDY OF THE GIMEMA CML WORKING PARTY

Author

Castagnetti, F, Gugliotta, G, Palandri, F, Levato, L, Abruzzese, E, Russo Rossi, A, Palmieri, F, Capucci, A, Pierri, I, Turri, D, Zaccaria, A, Cavazzini, F, Stagno, F, Musolino, C, Morandi, S, Breccia, M, Rege Cambrin, G, Amabile, M, I Testoni N, Iacobucci, Pane, F, Martinelli, G, Saglio, G, 1baccarani, M, and Rosti, G

Published
2010

122. One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly ( 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806

Author

Russo, D, Martinelli, G, Malagola, M, Colombi, C, Rosti, G, Amabile, M, Fogli, M, Turri, D, Mirto, S, Gobbi, M, Pierri, I, Vitolo, U, Pregno, P, Morra, E, Pungolino, E, Di Raimondo, F, Stagno, F, Foà, R, Alimena, G, Breccia, M, Nobile, F, Martino, B, Rambaldi, A, Intermesoli, T, Saglio, G, Rege Cambrin, G, Visani, G, Nicolini, G, de Fabritiis, P, Abruzzese, E, Fanin, R, Tiribelli, M, Galieni, P, Bigazzi, C, Specchia, G, Liso, V, Angelucci, E, Usala, E, Musolino, C, Russo, S, Gaidano, G, Lunghi, M, Lauria, F, Bocchia, M, Rodeghiero, F, D'Emilio, A, Bosi, A, Santini, V, Quarta, G, Girasoli, M, Fioritoni, G, Di Lorenzo, R, Testoni, N, De Vivo, A, Soverini, S, Iacobucci, I, and Baccarani, M

Published
2010

123. THE ROLE OF SPARC IN CHRONIC MYELOID LEUKEMIA

Author

Giallongo, C., La Cava, P., Tibullo, P., Ignazio Barbagallo, ALESSANDRA ROMANO, Del Fabro, V., Stagno, F., Chiarenza, A., Spina, P., Branca, A., Stefania Stella, Paolo VIGNERI, Palumbo, Giuseppe Alberto Maria, and Francesco Di Raimondo

Published
2010

125. IMPROVING ON IMATINIB FOR TARGETED THERAPY OF CHRONIC MYELOID LEUKEMIA: FIRST LINE TREATMENT WITH NILOTINIB 800 MG DAILY RESULTS IN UNPRECEDENTEDLY HIGH RATE OF RAPID, 'DEEP' AND STABLE MOLECULAR RESPONSES - RESULTS OF A PHASE 2 TRIAL OF THE GIMEMA CML WORKING PARTY

Author

Martinelli, G, Poerio, A, Soverini, S, Saglio, G, Pane, F, Castagnetti, F, Capucci, A, Tiribelli, M, Stagno, F, Palandri, F, Gugliotta, G, Zaccaria, A, Intermesoli, T, Martino, B, Bocchia, M, Cedrone, M, Testoni, N, Amabile, M, Iacobucci, I, Breccia, M, Alimena, G, Levato, L, Baccarani, M, and Rosti, G

Published
2010

126. PRE-FINAL ANALYSIS OF THE PHASE II EXPLORATIVE STUDY OF INTERMITTENT IMATINIB (IM) TREATMENT (INTERIM) IN ELDERLY PH+ CML PATIENTS WITH STABLE COMPLETE CYTOGENETIC RESPONSE (CCGR) – EUDRACT NUMBER 2007-005102-42, CLINICALTRIALS.GOV NCT 00858806

Author

Russo, D, Martinelli, G, Malagola, M, Colombi, C, Rosti, G, Amabile, M, Fogli, M, Mirto, S, Turri, D, Gobbi, M, Pierri, I, Vitolo, U, Pregno, P, Morra, E, Pungolino, E, Di Raimondo, F, Stagno, F, Foà, R, Alimena, G, Breccia, M, Nobile, F, Martino, B, Rambaldi, R, Intermesoli, T, Saglio, G, Rege Cambrin, G, Visani, G, Nicolini, G, De Fabritiis, P, Abruzzese, E, Fanin, R, Tiribelli, M, Galieni, P, Bigazzi, C, Liso, V, Specchia, G, Angelucci, E, Usala, E, Musolino, C, Russo, S, Gaidano, G, Lunghi, M, Lauria, F, Bocchia, M, Rodeghiero, F, D’Emilio, A, Bosi, A, Santini, V, Quarta, G, Girasoli, M, Fioritoni, G, Di Lorenzo, R, Testoni, N, De Vivo, A, Soverini, S, Iacobucci, I, and Baccarani, M

Published
2010

127. UPDATE OF CYTOGENETIC AND MOLECULAR RESPONSE IN 88 ELDERLY PH+ CHRONIC MYELOID LEUKEMIA PATIENTS ENROLLED IN THE PHASE II EXPLORATIVE STUDY OF INTERMITTENT IMATINIB (IM) TREATMENT (INTERIM)

Author

Russo, Domenico, Rosti, G., Martinelli, G., Malagola, Michele, Mirto, S., Turri, D., Gobbi, M., Pierri, I., Vitolo, U., Pregno, P., Morra, E., Pungolino, E., Di Raimondo, F., Stagno, F., Foà, R., Alimena, G., Breccia, M., Nobile, F., Martino, B., Rambaldi, A., Intermesoli, T., Saglio, G., Rege Cambrin, G., Visani, G., Nicolini, G., De Fabritiis, P., Abruzzese, E., Fanin, R., Tiribelli, M., Galieni, P., Bigazzi, C., Liso, V., Specchia, G., Angelucci, E., Usala, E., Musolino, C., Russo, S., Gaidano, G., Lunghi, M., Lauria, F., Bocchia, M., D’Emilio, A., Bosi, A., Sanitini, V., Quarta, G., Girasoli, M., Fioritoni, G., Di Lorenzo, R., Colombi, C., Fogli, M., Amabile, 2 M., Testoni, N., De Vivo, A., and Baccarani, M.

Published
2010

129. The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis

Author

Mori, S, Vagge, E, le Coutre, P, Abruzzese, E, Martino, B, Pungolino, E, Elena, C, Pierri, I, Assouline, S, D'Emilio, A, Gozzini, A, Giraldo, P, Stagno, F, Iurlo, A, Luciani, M, De Riso, G, Kim, D, Pirola, A, Petroccione, A, Lodolo D’Oria, A, Crivori, P, Piazza, R, GAMBACORTI PASSERINI, C, MORI, SILVIA, PIROLA, ALESSANDRA, PIAZZA, ROCCO GIOVANNI, GAMBACORTI PASSERINI, CARLO, Mori, S, Vagge, E, le Coutre, P, Abruzzese, E, Martino, B, Pungolino, E, Elena, C, Pierri, I, Assouline, S, D'Emilio, A, Gozzini, A, Giraldo, P, Stagno, F, Iurlo, A, Luciani, M, De Riso, G, Kim, D, Pirola, A, Petroccione, A, Lodolo D’Oria, A, Crivori, P, Piazza, R, GAMBACORTI PASSERINI, C, MORI, SILVIA, PIROLA, ALESSANDRA, PIAZZA, ROCCO GIOVANNI, and GAMBACORTI PASSERINI, CARLO

Abstract

Introduction. Chronic myeloid leukemia (CML) patients (pts) treated with imatinib first line achieve complete cytogenetic response (CCyR) in > 70% of cases and major molecular response (MMR) in 18-58%. These pts have a life expectancy similar to the general population. However even undetectable BCR-ABL may not equate to eradication of the disease because of the sensitivity of Q-RT-PCR. A new diagnostic method, the digital-PCR (dPCR), able to detect 1 BCR-ABL+ cell out of 107 cells, has been recently developed (Goh HG et al., 2011). dPCR corresponds to a 100 fold increase in sensitivity as compared to Q-RT-PCR. Therefore, dPCR by assessing the presence of minimal residual disease with higher sensitivity, could potentially identify pts in whom CML has been eradicated. Aims. The Imatinib Suspension And Validation (ISAV) study is aimed at validating the capability of dPCR to predict relapses after imatinib discontinuation in CML pts with negative Q-RT-PCR results. Methods. This study involves 15 sites, 10 in Italy and 1 in each of the following countries: Germany, Spain, The Netherlands, Canada and Israel. CML pts (Chronic or Accelerated Phase) under imatinib therapy since more than 2 years and in complete molecular remission (CMR) were eligible for this study. Patients had to be in CMR for at least 18 months (mts), with a minimum of 3 Q-RT-PCR performed at their own sites. After signing the informed consent, blood samples are obtained for dPCR and the pts discontinue imatinib therapy. Standard Q-RT-PCR is performed monthly (mts 1-6) and then bimonthly for 36 mts to assess the maintenance of the molecular remission. The loss of molecular remission is defined as two consecutive positive Q-RT-PCR tests with at least one BCR-ABL/ABL value above 0.1%. Patients losing molecular remission resume imatinib treatment at the same dosage used before interruption. Patients’ quality of life during imatinib discontinuation/resumption is evaluated through the EORTC – C30 Quality of

Published
2014

130. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

Author

Breccia, M, Luciano, L, Latagliata, R, Castagnetti, F, Ferrero, D, Cavazzini, F, Trawinska, Mm, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Crisà, E, Musto, P, Gozzini, A, Cavalli, L, Montefusco, E, Iurlo, A, Russo, S, Cedrone, M, Rossi, Ar, Pregno, P, Endri, M, Spadea, A, Molica, M, Giglio, G, Celesti, F, Sora', Federica, Storti, Sergio, D'Addosio, A, Cambrin, Gr, Isidori, A, Sica, Simona, Abruzzese, E, Speccha, G, Rosti, G, Alimena, G., Sora', Federica (ORCID:0000-0002-9607-5298), Storti, S (ORCID:0000-0002-4374-3985), Sica, Simona (ORCID:0000-0003-2426-3465), Breccia, M, Luciano, L, Latagliata, R, Castagnetti, F, Ferrero, D, Cavazzini, F, Trawinska, Mm, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Crisà, E, Musto, P, Gozzini, A, Cavalli, L, Montefusco, E, Iurlo, A, Russo, S, Cedrone, M, Rossi, Ar, Pregno, P, Endri, M, Spadea, A, Molica, M, Giglio, G, Celesti, F, Sora', Federica, Storti, Sergio, D'Addosio, A, Cambrin, Gr, Isidori, A, Sica, Simona, Abruzzese, E, Speccha, G, Rosti, G, Alimena, G., Sora', Federica (ORCID:0000-0002-9607-5298), Storti, S (ORCID:0000-0002-4374-3985), and Sica, Simona (ORCID:0000-0003-2426-3465)

Abstract

We applied Charlson comorbidity index (CCI) stratification on a large cohort of chronic myeloid leukemia (CML) very elderly patients (>75 years) treated with imatinib, in order to observe the impact of concomitant diseases on both compliance and outcome. One hundred and eighty-one patients were recruited by 21 Italian centers. There were 95 males and 86 females, median age 78.6 years (range 75-93.6). According to Sokal score, 106 patients were classified as intermediate risk and 55 as high risk (not available in 20 patients). According to CCI stratification, 71 patients had score 0 and 110 a score ≥ 1. Imatinib standard dose was reduced at start of therapy (200-300 mg/day) in 68 patients independently from the evaluation of baseline comorbidities, but based only on physician judgement: 43.6% of these patients had score 0 compared to 34% of patients who had score ≥ 1. Significant differences were found in terms of subsequent dose reduction (39% of patients with score 0 compared to 53% of patients with score ≥ 1) and in terms of drug discontinuation due to toxicity (35% of patients with score 0 vs 65% of patients with score ≥ 1). We did not find significant differences as regards occurrence of hematologic side effects, probably as a consequence of the initial dose reduction: 39% of patients with score 0 experienced grade 3/4 hematologic toxicity (most commonly anemia) compared to 42% of patients with score ≥ 1. Independently from the initial dose, comorbidities again did not have an impact on development of grade 3/4 non-hematologic side effects (most commonly skin rash, muscle cramps and fluid retention): 62% of patients with score 0 compared to 52.5% of patients with score ≥ 1. Notwithstanding the reduced dose and the weight of comorbidities we did not find significant differences but only a trend in terms of efficacy: 66% of patients with score 0 achieved a CCyR compared to 54% of patients with score ≥ 1. Comorbidities appeared to have an impact on median OS (40.8

Published
2014

131. Results of high dose of imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase trial of the GIMEMA Working Party

Author

Castagnetti, F, Palandri, F, Amabile, M, Testoni, N, Luatti, S, Soverini, S, Iacobucci, I, Breccia, M, Rege Cambrin, G, Stagno, F, Specchia, G, Galieni, P, Iuliano, F, Pane, F, Saglio, G, Alimena, G, Martinelli, G, Baccarani, M, Rostilevis, A, Pini, M, Bigazzi, C, Liso, V, Bassan, R, Intermesoli, T, Marzocchi, G, Capucci, A, Rossi, G, Girasoli, M, Giustolisi, R, Levato, L, Peta, A, Musolino, Caterina, Luciano, L, Rotoli, B, Cilloni, D, Fava, C, Semenzato, G, Musso, M, Porretto, F, Barulli, S, Visani, G, Di Lorenzo, R, Fioritoni, G, Trabacchi, E, Vallisa, D, Leone, G, Sica, S, Abruzzese, E, Foà, R, Petti, Mc, Bocchia, M, Lauria, F, Gherlinzoni, F, Gallo, E, and Pregno, P.

Published
2009

133. LONG-TERM FOLLOW-UP AND SAFETY OF DASATINIB IN CML/ALL PH1+ IMATINIB RESISTANT PATIENTS IN A COMPASSIONATE USE PROGRAM

Author

Gozzini, A, Stagno, F, Rege Cambrin, G, Luciano, L, Breccia, M, Abruzzese, E, Martinelli, G, Orlandi, E, Gobbi, M, Pregno, P, Sica, S, Pungolino, E, Angelucci, E, Musso, M, Bruno, B, Galimberti, S, Nieddu, R, Specchia, G, Kropp, Mg, Annunziata, M, Musto, P, Cervellera, P, Carella, Am, Pini, M, Radaelli, F, Meneghini, V, Russo, D, Montefusco, E, Marasca, R, and Gaidano, G

Published
2009

137. PHASE II MULTICENTRIC EXPLORATIVE STUDY OF INTERMITTENT IMATINIB (IM) TREATMENT (INTERIM) IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA (CML) WHO ACHIEVED A STABLE COMPLETE CYTOGENETIC RESPONSE (CCGR) WITH STANDARD IM THERAPY

Author

Russo, D., Rosti, G., Martinelli, G., Malagola, M., Mirto, S., Turri, D., Gobbi, M, Pierri, I., Vitolo, U., Pregno, P., Di Raimondo, F., Stagno, F., Foà, R., Alimena, G., Breccia, M, Rambaldi, R., Intermesoli, T, Saglio, G., Rege Cambrin, G., Visani, G., Nicolini, G., De Fabritiis, P., Abruzzese, E., Nobile, F., Martino, B., Fanin, R., Tiribelli, M., Galieni, P., Bigazzi, C., Liso, V., Specchia, G., Angelucci, E., Usala, E., Musolino, C., Russo, S., Gaidano, G. ., Lunghi, M., Lauria, F., Bocchia, M., Quarta, G., Girasoli, M., Bosi, A., Santini, V., Fioritoni, G., Di Lorenzo, R., Colombi, C., Fogli, M., Amabile, M., and De Vivo, A. Baccarani M.

Published
2009

138. Phase II multicentric explorative study of Intermittent Imatinib (IM) treatment (INTERIM) in elderly patients with Ph+ chronic myeloid leukemia (CML) who achieved a stable complete cytogenetic response (CCgR) with standard IM therapy

Author

Russo, Domenico, Rosti, G, Martinelli, G, Malagola, Michele, Mirto, S, Turri, D, Gobbi, M, Pierri, I, Vitolo, U, Pregno, P, Di Raimondo, F, Stagno, F, Foà, R, Alimena, G, Breccia, M, Rambaldi, A, Intermesoli, T, Saglio, G, Rege Cambrin, G, Visani, G, Nicolini, G, De Fabritiis, P, Abruzzese, E, Nobile, F, Martino, B, Fanin, R, Tiribelli, M, Galieni, P, Bigazzi, C, Liso, V, Specchia, G, Angelucci, E, Usala, E, Musolino, C, Russo, S, Gaidano, G, Lunghi, M, Lauria, F, Bocchia, M, Quarta, G, Girasoli, M, Bosi, A, Santini, V, Fioritoni, G, Di Lorenzo, R, Colombi, C, Fogli, M, Amabile, M, De Vivo, A, and B. a. c. c. a. r. a. n. i. M.

Published
2009

139. Occurence of pleural effusions during dasatinib treatment in elderly chronic myelogenous leukemia patients

Author

Latagliata, R., Breccia, M., Stagno, F., Luciano, L., Gozzini, A., Annunziata, M., Matteis, S., Albano, F., Ulisciani, S., Pregno, P., Pacilli, M., Abruzzese, E., Martino, B., Tiribelli, M., Avanzini, P., Pacilli, L., Paolo VIGNERI, Fabbricini, R., Russo Rossi, A., Sica, S., Vitolo, U., Montefusco, E., Fava, C., Ferrara, F., Santini, V., Pane, F., Francesco Di Raimondo, and Alimena, G.

Published
2009

145. THE SCREEN PROJECT: A CML DATA REGISTRY IN SICILY AND CALABRIA

Author

Stagno, F, Vigneri, Paolo, Stella, S, DEL FABRO, V, Massimino, M, Cupri, A, Turri, D, Abbadessa, V, Brugiatelli, M, Morabito, F, Musolino, C, Russo, M, Guglielmo, P, Pagnucco, G, Martino, B, Porretto, F, Rizzo, M, Antolino, A, Messina, A, Giustolisi, R, and DI RAIMONDO, Francesco

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results